Corvus Pharmaceuticals (CRVS) Long-Term Investments (2020 - 2026)

Corvus Pharmaceuticals' Long-Term Investments history runs 7 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• In Q1 2026, Long-Term Investments fell 12.95% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (down 12.95% YoY), while the FY2025 annual figure was $11.0 million, down 12.35% from the prior year.
• Long-Term Investments was $10.5 million for Q1 2026 at Corvus Pharmaceuticals, down from $11.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $33.4 million in Q1 2022 to a low of $10.5 million in Q1 2026.
• Historically, Long-Term Investments has averaged $17.6 million across 5 years, with a median of $16.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments fell 10.11% in 2022, then slumped 40.3% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $21.9 million in 2022, then declined by 26.3% to $16.1 million in 2023, then retreated by 22.22% to $12.5 million in 2024, then fell by 12.35% to $11.0 million in 2025, then retreated by 4.5% to $10.5 million in 2026.
• The last three Long-Term Investments figures came in at $10.5 million (Q1 2026), $11.0 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.